Validation period: 1/30/2023, 12:10:19 PM - 3/1/2023, 10:10:19 PM
BMJ Journals logo
Home/Top cited articles
Email alerts

Top cited articles

Acceptance rate:
17%
Time to first decision with review:
27 days*
Acceptance to publication:
9 days*
Impact Factor (JCR):
28.003
Impact Factor rank (JCR):
3/34
Citescore:
28.5
*median number of days
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study Furer, Victoria; Eviatar, Tali; Zisman, Devy; et al 10.1136/annrheumdis-2021-220647 Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry Strangfeld, Anja; Schafer, Martin; Gianfrancesco, Milena A.; et al 10.1136/annrheumdis-2020-219498 Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort Geisen, Ulf M.; Berner, Dennis K.; Tran, Florian; et al 10.1136/annrheumdis-2021-220272 Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease Haberman, Rebecca H; Herati, Ramin Sedaghat; Simon, David; et al 10.1136/annrheumdis-2021-220597 SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity Mrak, Daniel; Tobudic, Selma; Koblischke, Maximilian; et al 10.1136/annrheumdis-2021-220781 Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression Prendecki, Maria; Clarke, Candice; Edwards, Helena; et al 10.1136/annrheumdis-2021-220626 Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis Akiyama, Shintaro; Hamdeh, Shadi; Micic, Dejan;et al 10.1136/annrheumdis-2020-218946 Update on the diagnosis and management of systemic lupus erythematosus Fanouriakis, Antonis; Tziolos, Nikolaos; Bertsias, George; et al 10.1136/annrheumdis-2020-218272 SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases Simon, David; Tascilar, Koray; Fagni, Filippo; et al 10.1136/annrheumdis-2021-220461
EULAR definition of difficult-to-treat rheumatoid arthritis Nagy, Gyorgy; Roodenrijs, Nadia M. T.; Welsing, Paco M. J.; et al 10.1136/annrheumdis-2020-217344 Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases Sparks, Jeffrey A.; Wallace, Zachary S.; Seet, Andrea M.; et al 10.1136/annrheumdis-2021-220418 Microenvironment in subchondral bone: predominant regulator for the treatment of osteoarthritis Hu, Wenhui; Chen, Yueqi; Dou, Ce; Dong, Shiwu 10.1136/annrheumdis-2020-218089 Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases Boyarsky, Brian J; Ruddy, Jake A; Connolly, Caoilfhionn M; et al 10.1136/annrheumdis-2021-220289 Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database Hoffmann-Vold, Anna-Maria; Allanore, Yannick; Alves, Margarida; et al 10.1136/annrheumdis-2020-217455 SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response Bonelli, Michael Markus; Mrak, Daniel; Perkmann, Thomas; et al 10.1136/annrheumdis-2021-220408 High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases Ruddy, Jake A.; Connolly, Caoilfhionn Marie; Boyarsky, Brian J.; et al 10.1136/annrheumdis-2021-220656 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis Robson, Joanna C.; Grayson, Peter C.; Ponte, Cristina; et al 10.1136/annrheumdis-2021-221795 Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry Machado, Pedro M.; Lawson-Tovey, Saskia; Strangfeld, Anja; et al 10.1136/annrheumdis-2021-221490
eular-75 logoeular-textbooks logo
CONTENTrss-icontwitter-iconfacebook-iconsoundcloud-iconyoutube-icon
bmj-footer-logo
Website Terms & ConditionsPrivacy & CookiesContact BMJCookie settingsOnline ISSN: 1468-2060 Print ISSN: 0003-4967Copyright © 2023 BMJ Publishing Group Ltd & European Alliance of Associations for Rheumatism. All rights reserved.